Chronic lower respiratory diseases (CLRDs) are the fourth leading cause of death in the United States. To support investigations into CLRD risk determinants and new approaches to primary prevention, we aimed to harmonize and pool respiratory data from US general population-based cohorts. Data were obtained from prospective cohorts that performed prebronchodilator spirometry and were harmonized following 2005 ATS/ERS standards. In cohorts conducting follow-up for noncardiovascular events, CLRD events were defined as hospitalizations/deaths adjudicated as CLRDrelated or assigned relevant administrative codes. Coding and variable names were applied uniformly. The pooled sample included 65,251 adults in 9 cohorts followed-up for CLRD-related mortality over 653,380 person-years during 1983-2016. Average baseline age was 52 years; 56% were female; 49% were never-smokers; and racial/ethnic composition was 44% white, 22% black, 28% Hispanic/Latino, and 5% American Indian. Over 96% had complete data on smoking, clinical CLRD diagnoses, and dyspnea. After excluding invalid spirometry examinations (13%), there were 105,696 valid examinations (median, 2 per participant). Of 29,351 participants followed for CLRD hospitalizations, median follow-up was 14 years; only 5% were lost to follow-up at 10 years. The NHLBI Pooled Cohorts Study provides a harmonization standard applied to a large, US population-based sample that may be used to advance epidemiologic research on CLRD.
million US Emergency Department visits in 2014 (8) and are the main driver of US CLRD costs, which are projected to exceed $100 billion annually (11, 12) .
There remain important knowledge gaps regarding risk determinants for CLRD and its progression. While smoking is the major known risk factor for COPD, further investigation is needed regarding the large minority of COPD that occurs in never-smokers (13) (14) (15) , the risks of light and nondaily smoking (more prevalent in contemporary, multiethnic populations (16, 17) ), the significance of maximally attained lung function in early adulthood (18) , the relevance of developmental and early-life factors to lifetime CLRD risk (19) , and the occurrence of CLRD symptoms and clinical events in persons who do not meet standard diagnostic criteria for COPD or asthma (20) (21) (22) (23) . In addition, many prior studies were conducted in relatively modest-sized and mainly non-Hispanic white samples, limiting statistical power and generalizability to the multiethnic US population, in which race/ethnicity, geography, and socioeconomics are known to affect lung function and CLRD risk (24) (25) (26) (27) (28) (29) (30) (31) .
Population-based cohorts remain fundamental to understanding the natural history of CLRD and determinants of disease incidence, which are particularly relevant to developing and targeting primary prevention strategies (32) . Since the 1970s, numerous US cohorts have collected data relevant to CLRD epidemiology, including spirometry, CLRD hospitalizations and mortality, and time-varying smoking exposures-measures that are lacking from National Health and Nutrition Examination Survey and administrative data sets (27, 33) . While data collection has been highly standardized, data management has varied across studies, and there is, to our knowledge, no standard coding taxonomy for these data.
The potential benefits of harmonizing and pooling US cohort data include sufficient samples to enhance statistical precision for subgroup analyses and adequate follow-up for analyses of incident CLRD-related clinical events (34, 35) . However, the need for systematic validation and reconciliation of previously collected data was recognized as a potential barrier to pooling (35) and a limitation to meta-analytical approaches (36, 37) , motivating contemporary interest in phenotype harmonization across cohorts (38, 39) . In this work, we describe our approach to harmonization of data on lung function, respiratory events, and other relevant respiratory covariates across 9 US prospective cohort studies in the NHLBI Pooled Cohorts Study.
METHODS

Cohorts
The NHLBI Pooled Cohorts Study aimed to include all large National Heart, Lung, and Blood Institute (NHLBI)-funded prospective cohorts that measured spirometry (Web Figure 1 , available at https://academic.oup.com/aje) (40) (41) (42) (43) (44) (45) (46) (47) (48) . Most studies were initially funded to study cardiovascular epidemiology and were designed to capture target age ranges and racial/ethnic groups, as summarized in Table 1 .
All studies were approved by institutional review boards at participating institutions, and all participants provided written informed consent. Participants who did not consent to having their data analyzed for noncardiovascular research were excluded from the present work.
Ancillary study and/or data analysis approvals, as well as data use agreements, were obtained from each cohort, and data were centralized at Columbia University. Investigators from all cohorts-in particular, those chairing pulmonary working groups and spirometry reading centers-were invited to collaborate and participate in regular teleconferences and in-person meetings.
Harmonization
All available data and data dictionaries were requested from each cohort for the main respiratory measures (spirometry, events, symptoms, diagnoses, medications), inhalational exposures (smoking, occupational, environmental), and standard sociodemographic and anthropometric variables. Variables available in 2 or more cohorts were considered potentially suitable for harmonization and pooling.
Consistent with phenotype harmonization approaches in the Trans-Omics for Precision Medicine (TopMED) Project (38) , which is performing whole genome sequencing and collecting other "-omics" data in a subset of the NHLBI Pooled Cohorts, potentially harmonizable variables were first reviewed qualitatively by review of data dictionaries and study protocols, with cohort-specific investigator and data analyst input. They were next evaluated quantitatively, with comparison of means, variances, outliers, and missing data.
Within-individual data were used to minimize missing data and identify inconsistencies. Logic rules were applied (e.g., current smokers could not subsequently be classified as never-smokers; details available at the study website (49) ). Outlier values were checked against repeated measurements in the same subject and reviewed by 3 coauthors (E.C.O., P.P.B., R.G.B.) to determine which extreme values should be recoded to last-valuecarried-forward or missing. All recodings were catalogued.
A subset of the data (sociodemographic factors, anthropometry, smoking variables) was independently reharmonized by 2 investigators (Y.Z., A.E.M.) and results were compared. Any inconsistencies were investigated and corrected.
Straightforward harmonized variable names were developed and standardized coding rubrics (e.g., "0" = "no," "1" = "yes") were applied (Web Table 1 ). Categories were collapsed to align with the cohort(s) providing the fewest categories (least precision) for a given variable.
Variable-and cohort-specific harmonization protocols are provided at the study website (49) . Additional participant-level quality control (QC) data are available on request, with permission from the relevant cohorts.
Spirometry
Lung function was measured using water-seal, dry-rollingseal, or one model of flow-sensing spirometers. Many cohorts used similar or identical equipment, spirometry reading centers, and protocols. One investigator (P.L.E.) ran the spirometry reading centers and designed the protocols for Atherosclerosis Risk in vital capacity (FVC) ratio <0.70 or less than the lower limit of normal (50, 51) . Spirometry protocols were designed based upon American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines. Because the cohorts were examined from 1971 to the present-and ATS/ERS standards were issued and revised in 1979, 1987, 1994 , and 2005 (50-54)-there was modest heterogeneity in protocols, QC, and reporting standards across cohorts and, in some cases, among repeated examinations within cohorts.
We therefore developed a spirometry quality grading rubric based upon current (2005) ATS/ERS standards (50) ( Table 2) . Valid spirometry was defined as acquisition of ≥2 curves meeting acceptability criteria (50) (51) (52) (53) (54) , with the 2 largest lung volumes reproducible within 150 mL (50). Spirometry not meeting this standard was defined as invalid. In sensitivity analyses, the 1994 reproducibility standard of <200 mL was used (54) .
Reproducibility of the 2 largest volumes was further used to classify valid spirometry into grades A (<100 mL) and B (<150 mL), which met 2005 criteria (50), and C (<200 mL), which met 1994 but not 2005 repeatability criteria. Grade D was defined by nonreproducibility (>200 mL) or only 1 acceptable curve, and grade F was defined by nonreproducibility (>250 mL) or failure to obtain 1 acceptable curve.
FEV1 and FVC were graded independently. Best FEV1 and best FVC were used to calculate FEV1/FVC, which was classified as valid if both FEV1 and FVC measurements were valid.
This grading system was previously applied by 3 coauthors (P.L.E., J.H., R.G.B.) in 4 cohorts (ARIC Examination 5, CHS, HCHS/SOL, MESA) and also applied in the Strong Heart Study (SHS). For the remaining cohorts and examinations, the grading rubric was adapted based upon the data available, as summarized in Table 2 .
Events
All-cause mortality was ascertained in all 9 cohorts. Five cohorts (Cardiovascular Risk Development in Young Adults (CARDIA), CHS, Health, Aging and Body Composition (HABC), HCHS/SOL, SHS) adjudicated noncardiovascular causes of death, including CRLD mortality, via protocolized medical record review by a clinical events committee. Two cohorts that did not adjudicate respiratory and CLRD mortality (ARIC, MESA) nonetheless collected ICD data for all deaths.
Only 2 cohorts (HABC, HCHS/SOL) were designed to prospectively ascertain and adjudicate CLRD hospitalizations (55) . A subset of MESA deaths and hospitalizations was retrospectively adjudicated for CLRD (22, 56) . Four cohorts (ARIC, CHS, HCHS/SOL, MESA) collected ICD data for all hospitalizations occurring over follow-up. CARDIA collected only self-reported CLRD hospitalization data, which appeared to be underreported (cumulative incidence of reported CLRD hospitalizations <1%); hence, these data were not harmonized. Noncardiovascular hospitalization data were not available in SHS, and neither CLRD mortality nor CLRD hospitalization data were available in FHS-O or JHS at the time of publication (August 2018).
To supplement adjudicated respiratory endpoints in cohorts collecting diagnosis-code data for deaths and hospitalizations, we selected all events assigned diagnostic codes for asthma (International Classification of Diseases, Ninth Revision (ICD-9): 493, ICD-10: J45-J46), COPD (ICD-9: 496, ICD-10: J44), chronic bronchitis (ICD-9: 490-491, ICD-10: J40-J42), and/or emphysema (ICD-9: 492, ICD-10: J43).
According to an algorithm we previously developed in HCHS/SOL and validated in MESA (56), severe obstructive lung events (SOLE) were defined as hospitalizations or deaths adjudicated as primarily attributable to CLRD or, if adjudication was lacking, those with CLRD coded as the primary discharge diagnosis or as the underlying cause of death. CLRD-related events were defined as hospitalizations or deaths adjudicated as primarily or secondarily attributable to CLRD, or, if adjudication was lacking, those with CLRD listed in any ICD code position.
Clinical lung disease and symptoms
Participants in all cohorts were asked to report prior physician diagnoses of asthma, COPD, chronic bronchitis, or emphysema. Because the term COPD was not well-known to the general public prior to the 21st Century, self-reported chronic bronchitis and emphysema were coded as self-reported COPD.
Utilization of inhaled bronchodilators and inhaled corticosteroids was assessed by self-report or medication inventory in all cohorts at each examination (57, 58) .
Dyspnea was assessed in all cohorts. In ARIC, CARDIA, CHS, MESA, and SHS, it was classified using the modified Medical Research Council (mMRC) scale (59), additionally allowing definition of mMRC-classified chronic bronchitis.
Smoking
Smoking status was assessed by standard questionnaire items in all cohorts and all examinations (60). Pack-years were selfreported at baseline examinations and updated based upon time-variant cigarettes-per-day as described on the study website. Secondhand smoke exposure was self-reported in selected cohorts.
Covariates
In all cohorts, race/ethnicity, sex, and educational attainment were self-reported. Race/ethnicity was defined using the 2000 US Census approach (61), which is comparable to the proposed 2020 Census approach (62) . Body mass index was calculated from height and weight. Cohort-specific procedures are described on the study website.
Statistical analysis
The baseline characteristics of the pooled sample and subsamples with valid spirometry and CLRD events follow-up were tabulated and compared.
Within-and between-subject variability in lung function was compared before and after exclusion of invalid spirometry using within-and between-subject variances and their ratio, the intraclass correlation, in mixed models including adjustment for age, sex, height, and race/ethnicity. The number of lung function outliers, defined by values ≥2.5 standard deviations from the mean, was also assessed, as was the proportion of the population with ≥15% improved lung function over time, as this is not consistent with long-accepted physiologic declines in lung function in middle and older ages. Results were compared using 2005 versus 1994 reproducibility standards (50, 54) .
Statistical analyses were performed in SAS, version 9.4 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
The NHLBI Pooled Cohorts Study included 65,251 participants from all 9 large US population-based prospective cohort studies that measured spirometry in adults (Table 3 ). The mean age at baseline examination was 52 ± 16 years; there were 17,005 (26%) participants who were 18-45 years old, the age range during which adults typically attain maximum lung function (63, 64) . Fifty-six percent were female. Compared with the current US population, nonwhites were oversampled: 44% of participants were white, 22% were black, 28% were Hispanic/ Latino, 5% were American Indian, and 1% were Asian.
After between-and within-individual QC and harmonization, missing data for demographic factors and self-reported lung disease were infrequent or nonexistent (Web Table 2 ). Smoking status was missing for 195 participants (0.3%), and pack-years were missing for 1,713 (2.6%). Among data undergoing independent reharmonization, one incongruence related to selection of a single variable was identified in one cohort and reconciled; otherwise, the harmonization was fully replicated.
Spirometry completion
All cohorts selected all participants for spirometry at baseline, except for MESA. Spirometry was performed in MESA as part of an ancillary study that randomly selected 4,483 participants in Examination 3 or 4 (65) in addition to all 257 new recruits in the MESA Air Pollution Study (66) . Of 65,251 participants in the NHLBI Pooled Cohort Study, 2,331 (the remainder of MESA participants; 4%) were consequently not selected, and 3,408 (5%) additional participants from all studies declined spirometry (Figure 1 ).
Of 59,512 participants attempting at least 1 spirometry examination, 46,440 (78%) had valid spirometry at all attempted examinations, 4,499 (8%) participants had no valid spirometry, and 8,573 (14%) had valid spirometry as some but not all examinations.
Among 55,013 participants with at least 1 valid spirometry measurement, the median number of valid spirometry measurements was 2 (interquartile range, 1-3), yielding 105,696 spirometry examinations over a median of 2.80 (interquartile range, 0-8.93) years. Fifty percent (n = 27,328) had at least 1 subsequent valid measurement of spirometry, and 25% (n = 13,767) had 3 or more. Four or more valid measurements were available in 6,493 participants, all from ARIC/JHS corecruits, CARDIA, or FHS-O.
Eighty-four percent (n = 53,191) of participants had both valid spirometry and complete sociodemographic, anthropometric, and smoking data; of these, 26,222 (49%) had more than 1 valid measurement of spirometry.
Spirometry quality
Fifty-four percent of spirometry examinations (n = 65,294) were of the highest quality (grade A), while absence of acceptable a Reproducibility pertains to largest 2 values of FEV1 or FVC. For grades A, B, and C, both acceptability and reproducibility criteria must be met or exceeded. For grades D and F, either acceptability or reproducibility criteria could be met in order to qualify for the grade (e.g., "D" spirometry in HCHS/SOL includes examinations with 2 FEV1 measurements that are 225 mL apart as well as examinations with only 1 acceptable curve).
b In ARIC Examinations 1-2, considerable QC information was available, but it corresponded poorly with the QC approach used in the main grading rubric. Based upon prior QC efforts applied in these ARIC data (43) , 2005 American Thoracic Society/European Respiratory Society acceptability criteria, and expert opinion, we classified as valid those spirometry examinations with 3 or more maneuvers attempted and none of the following technical errors: no flow-volume loop recorded or the computer started after the beginning of the forced exhalation; breath-hold leak >5% detected; submaximal participant effort; no plateau during forced exhalation; or incorrect spirometer calibration.
c CARDIA used a similar grading approach to ours in its year-20 examination, with only minor discrepancies that did not affect the distinction between valid and invalid spirometry. However, CARDIA had not applied this standard to the prior 4 CARDIA spirometry examinations (years 0, 2, 5, and 10). We therefore obtained full spirometry data from these examinations, including all available curves, and consistently applied CARDIA's own year-20 approach.
d FVC was not measured in CHS Examination 18; FEV6 (6 seconds) was therefore interpreted as FVC. e FHS-O Examinations 1 and 2, which were performed prior to the 1979 publication of American Thoracic Society/European Respiratory Society spirometry standards, were excluded. For FHS-O Examination 3, only the number of acceptable curves was available for QC review; to correspond best with our standardized rubric, we therefore dichotomized spirometry examinations into valid (≥2 acceptable curves) versus invalid (<2 acceptable curves). FHS-O provided data on lung volumes for all acceptable curves obtained in Examinations 5-7, and we therefore applied the CARDIA year-20 grading rubric to these data. In FHS-O Examinations 8-9, only the number of acceptable curves and their reproducibility within 5% were available; hence, these data were used to classify spirometry provisionally into grades A, B, D, and F.
f The HABC grading system defined grade A as <100 mL and B as <200 mL. Experience in other elderly cohorts (e.g., CHS) indicated that, among spirometry repeatable between 100 mL and 200 mL, repeatability <150 mL was much more frequent than 150-200 mL. Hence, HABC grade B was treated as grade B in our rubric.
g JHS provided data on lung volumes for all acceptable curves obtained in Examination 1, and we therefore applied the NHLBI Pooled Cohorts Study grading rubric to these data.
curves (grade F) was infrequent (n = 3,655, 3%) (Web Table 3 ; Web Figures 2-7) . Examinations completed earlier in calendar time had a lower proportion of valid spirometry, and quality mainly improved over subsequent examinations within cohorts. For example, FHS-O Examination 3, for which original QC data was very limited (Table 2) , had the lowest proportion of valid results (64.5%). FHS-O Examination 5, for which there was much more data available for QC purposes, also demonstrated relatively low proportion of valid spirometry (76.7%). This was not due to the grading rubric; exactly the same approach was used for FHS-O Examinations 6 and 7, in which valid proportions were 92% and 94%, respectively. Higher spirometry quality was also more frequently observed in younger participants, white participants, women, and neversmokers without airflow limitation. Nonetheless, due to the relatively high quality of spirometry measurements overall, exclusion of participants with invalid spirometry yielded a sample with similar baseline characteristics ( Table 3) .
As expected, within-and between-subject variability in FEV1 and FVC were lower among valid versus invalid spirometry measurements. Compared with valid FEV1 measurements, invalid measurements demonstrated higher variance (0.62 versus 0.57) and significantly lower intraclass correlations (0.73 versus 0.84, P < 0.0001). The number of outliers (>2.5 standard deviations) was higher (2.1% versus 1.2%), as was the proportion of participants showing an annual increase of ≥15% (1.4% versus 0.08%) (details provided in Web Table 3 ).
Application of the 1994 reproducibility standard permitted the inclusion of an additional 4,699 participants with grade C spirometry (Web Table 3 ). Compared with the intraclass correlation for grades A and B (0.89 and 0.87, respectively), the intraclass correlation for grade C was lower (0.85), but it was substantially higher than that for D and F (0.73 and 0.78, respectively). The spirometric characteristics of the sample were similar whether the 2005 or 1994 reproducibility standards were applied.
Events follow-up
Among 6 cohorts (ARIC, CARDIA, CHS, HABC, MESA, SHS) with CLRD mortality data available at the time of manuscript preparation (August 2018), there were 37,982 participants with a median of 16.4 (interquartile range, 11.9-24.4) years of follow-up, yielding 653,380 person-years of observation (Table 4) . A subset of 29,356 participants in 4 cohorts (ARIC, CHS, HABC, MESA) were additionally followed for CLRD hospitalizations over a median of 13.9 (interquartile range, 10.2-20.7) years, providing 410,320 person-years of observation for severe obstructive lung events and CLRD-related events. Of these, complete data for standard covariates and smoking were available for 28,398 (96.8%), and 26,935 (94.8%) had complete follow-up at 10 years. Only 19,880 (70.0%) and 15,563 (54.8%) had complete follow-up at 15 and 20 years, respectively, due in part to the fact that MESA is currently reporting a maximum of 14 years of follow-up.
Self-reported lung disease and symptoms Self-reported CLRD was complete for 96.2% of participants (Web Table 2 ). Eighty-nine percent (n = 54,387) had data on chronic bronchitis as classified by the modified Medical Research Council scale.
DISCUSSION
The NHLBI Pooled Cohorts Study harmonized and pooled respiratory data from 9 US prospective cohort studies, yielding a large, population-based sample that ranges from young adulthood to old age, spans over 50 years of observation, and reflects the racial/ethnic, socioeconomic, and geographic diversity in the United States. This work leverages 5 decades of research investment, highly standardized protocols, gold-standard measures, and prospective events surveillance with very high followup rates to apply, for the first time, contemporary spirometry standards as well as to define clinical CLRD endpoints using standardized methodology to all available US cohorts. The NHLBI Pooled Cohorts Study thereby provides a unique sample of US adults that may be used to advance epidemiologic research on CLRD, especially among population subgroups (e.g., women, racial/ethnic minorities, and never-smokers) underrepresented in the CLRD literature.
While the importance of data harmonization is drawing increasing attention from the research community (67-70)-driven, at least in part, by the growing availability of heterogeneous "big data"-a current search of PubMed (https://www. ncbi.nlm.nih.gov/pubmed/) for articles on "harmonization AND spirometry" yields zero records. This is despite the fact that standardization of spirometry measures, which are effortdependent, has been the subject of considerable attention from the clinical community, resulting in a series of evolving guidelines in recent decades (50) (51) (52) (53) (54) . In this work, exclusion of invalid spirometry reduced between-and within-individual variability, outliers, and lung-function trend irregularities, consistent with decreased measurement error. This was achieved without sacrificing the diversity or scale of the component cohorts.
While meta-analysis is frequently used to address differences in study designs and measurements (36, (71) (72) (73) , there are wellrecognized limitations to this approach, especially in the context of observational studies (74, 75) . In this work, we aimed to minimize within-study measurement error and between-study heterogeneity by standardized, longitudinal QC and harmonization, yielding data suitable for meta-analyses as well as for pooled analyses that may be more appropriate for epidemiologic analyses for which multiple sensitivity analyses are often required, stratification is of particular interest, and multivariate methods are indicated (76) . Indeed, in the context of increasing interest in harmonization and pooling (77) (78) (79) , NHLBI Pooled Cohorts Study investigators are collaborating actively with the TransOmics for Precision Medicine Project and the Cross-Cohort Collaboration to share the protocols and data described in this report with the shared goal of promoting precision epidemiology for CLRD as well as other diseases (38, 39) .
Strengths of the current work include the inclusion of 9 US epidemiologic cohorts, the systematic harmonization approach, and the expertise of leading pulmonologists and epidemiologists who collaborated in the development of the NHLBI Pooled Cohorts Study, most of whom were involved with the collection the original data. There are nonetheless several limitations and areas requiring further investigation and refinement.
The 9 cohorts included in this work collected high-quality data using highly standardized and often identical protocols; nonetheless, there were certainly distinct differences in measurement across cohorts, not to mention birth cohort and historical differences. This situation necessitated assumptions based upon a combination of empirical analyses, published standards, prior literature, and expert opinion, yet these were sometimes unverifiable. To mitigate these unavoidable uncertainties and to promote ongoing improvement, the present analysis and its supplemental materials describe and justify the current protocol in detail, and even more granular data on participant-level QC was recorded so that it may be made available to collaborators.
While excluding invalid spirometry is expected to minimize misclassification, applying reproducibility standards may also select out individuals with more severe lung disease (80) . Hence, beyond contemporary validity standards, we have provided more precise grading for consideration by investigators as they determine which measures to use for testing specific hypotheses. With respect to the potential application of reference equations to estimate percent-predicted lung function, recent work has raised concerns regarding misclassification contingent on age and race/ ethnicity (17, 51, 64) ; thus measured lung function values may be more suitable for epidemiological analyses, with relevant adjustment.
Most cohorts did not attempt representative sampling, so the NHLBI Pooled Cohorts Study is not directly representative of the US population. Nonetheless, all cohorts sample community-dwelling adults, and all major US racial/ethnic groups are represented in substantial proportions.
Postbronchodilator spirometry is important to clinical definition of COPD and asthma (7), yet postbronchodilator spirometry was available only for a limited number of participants in a few cohorts. Prebronchodilator spirometry remains nonetheless highly prognostic of health outcomes and is highly correlated with postbronchodilator measurements in the general population (81) .
In conclusion, the NHLBI Pooled Cohorts Study has harmonized and pooled data from 9 gold-standard NIH-funded epidemiologic cohorts in order to promote research on common and increasingly prevalent respiratory diseases that, especially in the case of COPD, lack effective medical therapies or preventive strategies beyond smoking cessation and avoidance. and U01-HL65521 and research grants R01-HL109315, R01HL109301, R01HL109284, R01HL109282, and R01HL109319). This work was also funded by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences.
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